



Intervening in the High-Risk Patient Before a CV Event: The Role of PCSK9 Inhibition

Get all of your burning questions
answered by the experts!



Milan Gupta

MD, FRCPC, FCCS, CPC(HC)

Assistant Professor, Department of Medicine,
University of Toronto
Medical Director,
Collaborative CME and Research Network
Brampton, ON



Lawrence A. Leiter

MD, FRCPC, FACP, FACE, FAHA, FACC

Division of Endocrinology and Metabolism,
St. Michael's Hospital
Professor of Medicine and Nutritional Sciences,
University of Toronto
Toronto, ON



Tuesday,

May 5, 2026

7:00 - 8:00 pm EDT

Join this engaging discussion on the
VESALIUS-CV trial with Dr. Lawrence
Leiter (Key Investigator).

Explore the role of evolocumab in preventing first major cardiovascular events in high-risk patients without prior MI or stroke, and gain practical insights for your clinical practice.

Learning Objectives

- Identification of high-risk patients without prior CV events
- Discuss the spectrum of primary vs. secondary CV prevention
- Learn about the role of evolocumab in patients with subclinical atherosclerosis or high-risk diabetes

Register at:
www.ccrnmd.com.



Developed By



For program inquiries, contact:
info@ccrnmd.com

This program has received unrestricted educational funding from Amgen.